Compare ResMed Inc. (RMD) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs T-Mobile Us Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while T-Mobile Us Inc trades at $177.98 (market cap $194.89B). The key difference: T-Mobile Us Inc is far larger — about 6.1× ResMed Inc.'s market cap, and T-Mobile Us Inc pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| RMD | TMUS | |
|---|---|---|
Market Cap | $31.89B | $194.89B |
Sector | Health | Media |
52-Week High | $283.28 | $241.67 |
52-Week Low | $182.82 | $167.65 |
Enterprise Value | $31.24B | $311.51B |
Dividend Yield | 1.19% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement with a 0.09% gain. The stock faces bearish technical signals but maintains strong fundamentals with consistent revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability margins. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss. The company announced a CFO transition effective February 2027 and continues strategic partnerships, including the Paramount+ Plaza naming rights deal announced September 8, 2026.
TMUS presents a compelling long-term opportunity with 80% analyst buy ratings and a $233.20 consensus price target implying 28% upside. However, rising debt levels (debt-to-asset ratio increased to 39.35% in 2025) and competitive broadband pricing pressures pose risks. The stock's valuation at 19x P/E appears reasonable given sector positioning and growth trajectory, though technical weakness suggests near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
